Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is being defined as the worst pandemic disease of modern times. Several professional health organizations have published position papers stating that there is no evidence to change the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the management of elevated blood pressure in the context of avoiding or treating COVID-19 infection. In this article, we review the evidence on the relationship between the renin-angiotensin-aldosterone system and COVID-19 infection. In agreement with current guidelines, patients with hypertension should continue taking antihypertensive medications as prescribed without interruption. Because ACEIs and ARBs are also used to retard the progression of chronic kidney disease, we suggest that these recommendations also apply to the use of these agents in chronic kidney disease. No differences generally exist between ARBs and ACEIs in terms of efficacy in decreasing blood pressure and improving other outcomes, such as all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease. The ACEIs are associated with cough secondary to accumulation of bradykinin and angioedema, and withdrawal rates due to adverse events are lower with ARBs. Given their equal efficacy but fewer adverse events, ARBs could potentially be a more favorable treatment option in patients with COVID-19 at higher risk for severe forms of disease.
Copyright © 2020. Published by Elsevier Inc.
Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.J Manag Care Pharm. 2011 Oct;17(8 Suppl):S1-14. doi: 10.18553/jmcp.2011.17.s8.1. J Manag Care Pharm. 2011. PMID: 22088101 Review.
Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.Adv Ther. 2019 Feb;36(2):278-297. doi: 10.1007/s12325-018-0859-x. Epub 2018 Dec 27. Adv Ther. 2019. PMID: 30591990 Free PMC article. Review.
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.JAMA Cardiol. 2020 Apr 23:e201624. doi: 10.1001/jamacardio.2020.1624. Online ahead of print. JAMA Cardiol. 2020. PMID: 32324209
Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?J Am Coll Cardiol. 2018 Apr 3;71(13):1474-1482. doi: 10.1016/j.jacc.2018.01.058. J Am Coll Cardiol. 2018. PMID: 29598869 Review.
Angioedema related to Angiotensin inhibitors.J Pharm Pract. 2014 Oct;27(5):461-5. doi: 10.1177/0897190014546101. Epub 2014 Aug 14. J Pharm Pract. 2014. PMID: 25124378 Review.
Cited by 1 article
COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?Pharmacol Res. 2020 May 13;158:104906. doi: 10.1016/j.phrs.2020.104906. Online ahead of print. Pharmacol Res. 2020. PMID: 32405229 Free PMC article. Review.